» Articles » PMID: 1973174

Clinically Nonfunctioning Pituitary Tumors Are Monoclonal in Origin

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1990 Jul 1
PMID 1973174
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Clinically nonfunctioning pituitary adenomas are benign neoplasms comprising approximately 25-30% of pituitary tumors. Little is known about the pathogenesis of pituitary neoplasia. Clonal analysis allows one to make the important distinction between a polyclonal proliferation in response to a stimulatory factor versus a monoclonal expansion of a genetically aberrant cell. We investigated the clonal origin of pituitary tumors using X-linked restriction fragment length polymorphisms at the phosphoglycerate kinase and hypoxanthine phosphoribosyl-transferase genes. Restriction enzymes were used to distinguish maternal and paternal X-chromosomes, and combined with a methylation-sensitive restriction enzyme to analyze allelic X-inactivation patterns in six pituitary adenomas. All six tumors showed a monoclonal pattern of X-inactivation. These data indicate that nonfunctioning pituitary adenomas are unicellular in origin, a result consistent with the hypothesis that this tumor type is due to somatic mutation.

Citing Articles

Association between Intracellular Calcium Signaling and Tumor Recurrence in Human Non-Functioning Pituitary Adenomas.

Santiago-Andres Y, Aquiles A, Taniguchi-Ponciano K, Salame L, Guinto G, Mercado M Int J Mol Sci. 2024; 25(7).

PMID: 38612778 PMC: 11011867. DOI: 10.3390/ijms25073968.


Pituitary tumours without distinct lineage differentiation express stem cell marker SOX2.

Lenders N, Thompson T, Chui J, Low J, Inder W, Earls P Pituitary. 2024; 27(3):248-258.

PMID: 38483762 PMC: 11150322. DOI: 10.1007/s11102-024-01385-0.


Research progress on the role of the Wnt signaling pathway in pituitary adenoma.

Wang W, Ma L, Zhao Y, Liu M, Ye W, Li X Front Endocrinol (Lausanne). 2023; 14:1216817.

PMID: 37780610 PMC: 10538627. DOI: 10.3389/fendo.2023.1216817.


The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.

Derwich A, Sykutera M, Brominska B, Rubis B, Ruchala M, Sawicka-Gutaj N Int J Mol Sci. 2023; 24(13).

PMID: 37446128 PMC: 10341524. DOI: 10.3390/ijms241310952.


Vascular anomalies in patients with growth hormone-secreting pituitary adenomas: illustrative case report and systematic review of the literature.

Spille D, Vorona E, Catalino M, Reuter G, Beckers A, Holling M Pituitary. 2022; 26(1):132-143.

PMID: 36508085 PMC: 9908726. DOI: 10.1007/s11102-022-01291-3.


References
1.
DeStephano D, Lloyd R, Pike A, Wilson B . Pituitary adenomas. An immunohistochemical study of hormone production and chromogranin localization. Am J Pathol. 1984; 116(3):464-72. PMC: 1900471. View

2.
Fearon E, Hamilton S, Vogelstein B . Clonal analysis of human colorectal tumors. Science. 1987; 238(4824):193-7. DOI: 10.1126/science.2889267. View

3.
Thakker R, Bouloux P, Wooding C, Chotai K, Broad P, Spurr N . Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med. 1989; 321(4):218-24. DOI: 10.1056/NEJM198907273210403. View

4.
Klibanski A, Shupnik M, Bikkal H, Black P, KLIMAN B, Zervas N . Dopaminergic regulation of alpha-subunit secretion and messenger ribonucleic acid levels in alpha-secreting pituitary tumors. J Clin Endocrinol Metab. 1988; 66(1):96-102. DOI: 10.1210/jcem-66-1-96. View

5.
Keith D, Singer-Sam J, Riggs A . Active X chromosome DNA is unmethylated at eight CCGG sites clustered in a guanine-plus-cytosine-rich island at the 5' end of the gene for phosphoglycerate kinase. Mol Cell Biol. 1986; 6(11):4122-5. PMC: 367182. DOI: 10.1128/mcb.6.11.4122-4125.1986. View